HLB PEP

HLB PEP is a South Korean biotechnology company and a subsidiary of the HLB Group, specializing in the development of peptide-based therapeutics. The company utilizes its proprietary PEP-STABLE platform technology to overcome the inherent limitations of peptides, such as short half-lives and low stability, enabling the creation of long-acting and highly potent drug candidates. Its lead program, PEP-001, is being developed for the treatment of sepsis and septic shock, while other pipeline assets target ophthalmic conditions like macular degeneration. HLB PEP aims to address critical unmet medical needs by leveraging its expertise in peptide engineering and drug delivery systems.